Significant Ownership of GREAT POINT PARTNERS LLC
- Notable people
- Jeffrey R. Jay, Mr. David Kroin, Ortav Yehudai, Lillian Nordahl
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for GREAT POINT PARTNERS LLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Dr. Jeffrey R. Jay, M.D - Dr. Jeffrey R. Jay, M.D - Senior Managing Member
- Manager location
- Greenwich, CT
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow GREAT POINT PARTNERS LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from GREAT POINT PARTNERS LLC
Significant Ownership of GREAT POINT PARTNERS LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| UNCY | Unicycive Therapeutics, Inc. | Common Stock, par value $0.001 per share | 10% | $7,228,095 | 11,473,166 | Great Point Partners, LLC | 31 Dec 2024 | ||
| SCYX | SCYNEXIS, Inc. | Common Stock, par value $0.001 per share | 10% | $7,101,055 | 7,978,713 | Great Point Partners, LLC | 31 Mar 2026 | ||
| PMN | ProMIS Neurosciences Inc. | Common Shares, no par value per share | 10% | $2,790,563 | 409,648 | Great Point Partners, LLC | 31 Dec 2025 | ||
| PMN | PROMIS NEUROSCIENCES INC. | Common Shares, No Par Value per Share | 10% | $400,714 | -$2,107,681 | 954,082 | -84% | Great Point Partners, LLC | 31 Mar 2026 |
| SLGL | Sol-Gel Technologies Ltd. | Ordinary Shares, par value NIS 1.00 per share | 8.4% | $11,561,684 | 274,363 | Great Point Partners, LLC | 24 Mar 2026 | ||
| AMANAT ACQUISITION CORP | Class A ordinary shares | 5.2% | 500,000 | Great Point Partners, LLC | 19 May 2026 | ||||
| OTLK | Outlook Therapeutics, Inc. | Common Stock, $0.001 par value per share | 5% | $4,484,400 | 2,220,000 | 0% | Great Point Partners, LLC | 30 Jun 2025 | |
| VTGN | Vistagen Therapeutics, Inc. | Common Stock, $0.001 par value per share | 5% | $1,521,317 | 2,055,834 | 0% | Great Point Partners, LLC | 31 Dec 2025 | |
| OPTN | OPTINOSE, INC. | Common Stock, $0.001 par value per share | 4.9% | $4,789,466 | -$3,369,457 | 526,315 | -41% | Great Point Partners, LLC | 31 Mar 2025 |
| UNCY | Unicycive Therapeutics, Inc. | Common Stock, par value $0.001 per share | 4.5% | $3,472,993 | 796,558 | 0% | Great Point Partners, LLC | 30 Sep 2025 | |
| ZURA | Zura Bio Limited | Class A Ordinary Shares | 4.4% | $25,422,058 | +$2,412,000 | 4,215,930 | +10% | Great Point Partners, LLC | 31 Mar 2026 |
| Inventiva S.A. | Ordinary shares, nominal value 0.01 Euro per share | 3.5% | 6,783,269 | -21% | Great Point Partners, LLC | 31 Dec 2025 | |||
| VOR | VOR BIOPHARMA INC. | Common Stock, $0.0001 par value per share | 3.3% | $18,578,651 | +$1,839,021 | 1,370,107 | +11% | Great Point Partners, LLC | 31 Dec 2025 |
| NGNE | NEUROGENE INC. | Common Stock, par value $0.000001 per share | 3% | $6,822,947 | 442,761 | Great Point Partners, LLC | 31 Dec 2024 | ||
| CNTX | Context Therapeutics Inc. | Common Stock | 2.4% | $5,864,860 | -$6,406,463 | 2,238,496 | -52% | Great Point Partners, LLC | 31 Mar 2026 |
Schedules 13D/G Reported by GREAT POINT PARTNERS LLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.